Story Poster
Photo by Rick Kimball/ISD
Notre Dame Football

ISD's Full Lid For Week

May 7, 2021
1,565

BAT SIGNAL GOES OUT

The Notre Dame coaching staff appears to be saying it is on the verge of adding a new member to the 2022 recruiting class.

Astute ISD subscribers have made their predictions in this update.


IRISH MAKE THEIR PRESENCE FELT ACROSS NATION

Notre Dame showed its first serious signs of promoting its players for the coming NIL Era by putting up billboards featuring their guys across the country. The move is also serving as a recruiting tool. 

Overall, a very forward-looking approach from the Irish, which is very encouraging.

ND SETTING NEW BAR FOR NIL RECRUITING


IRISH LOSE FORMER 5-STAR WR

Freshman wide receiver Jordan Johnson entered the transfer portal on Monday.

JORDAN JOHNSON ANNOUNCES TRANSFER


FIFTH-YEAR OL MOVES ON

Irish offensive lineman Dillan Gibbons announced that he was entering the transfer portal.

DILLAN GIBBONS ANNOUNCES TRANSFER


MORE BLUE-GOLD BREAKDOWN FROM UYEYAMA

ISD expert Jamie Uyeyama broke down Saturday’s Blue-Gold Game, looking at some good, some bad and some promising.

FILM DON’T LIE | 2021 SPRING GAME


JAMIE’S WEEKLY THOUGHTS

Jamie Uyeyama addresses the Jordan Johnson transfer, Marcus Freeman's third-down defense, an early look at FSU and more.

6 THOUGHTS ON A THURSDAY


ELITE 2023 DEFENDER EYEING JUNE STOP AT ND

Maryland defensive end Jason Moore says he’ll make the trip up to South Bend for a day while in Indianapolis for a basketball tournament next month.

One of the top defensive end targets in the country, Moore has already formed a solid relationship with Irish defensive line coach Mike Elston.

THE LATEST | NOTRE DAME & 2023 DE JASON MOORE


TOP TARGETS TALK NOTRE DAME FROM UA BALTIMORE

Updates on 2022 defensive back targets Sherrod Covil and Kevin Winston along with 2022 wide receiver Andre Greene and more.

UNDER ARMOUR BALTIMORE REGIONAL NOTEBOOK

 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.